The efficacy of a GM-CSF-producing oncolytic virus against an A20 lymphoma control was shown to be due to an oncoviral-induced release of tumor antigen that induced a CD8+ T-cell response that was able to slow the growth of untreated contralateral tumors, especially when combined with anti-CLTA-4 antibody [21]. Here, CD8A is linked to lymphoma.